216 related articles for article (PubMed ID: 29999516)
21. Vincristine: Can its therapeutic index be enhanced?
Moore A; Pinkerton R
Pediatr Blood Cancer; 2009 Dec; 53(7):1180-7. PubMed ID: 19588521
[TBL] [Abstract][Full Text] [Related]
22. Vincristine-induced peripheral neuropathy in pediatric cancer patients.
Mora E; Smith EM; Donohoe C; Hertz DL
Am J Cancer Res; 2016; 6(11):2416-2430. PubMed ID: 27904761
[TBL] [Abstract][Full Text] [Related]
23. Precision medicine to improve the risk and benefit of cancer care: genetic factors in vincristine-related neuropathy.
McLeod HL
JAMA; 2015 Feb; 313(8):803-4. PubMed ID: 25710656
[No Abstract] [Full Text] [Related]
24. Mir-pharmacogenetics of Vincristine and peripheral neurotoxicity in childhood B-cell acute lymphoblastic leukemia.
Gutierrez-Camino Á; Umerez M; Martin-Guerrero I; García de Andoin N; Santos B; Sastre A; Echebarria-Barona A; Astigarraga I; Navajas A; Garcia-Orad A
Pharmacogenomics J; 2018 Dec; 18(6):704-712. PubMed ID: 29282364
[TBL] [Abstract][Full Text] [Related]
25. Characterising vincristine-induced peripheral neuropathy in adults: symptom development and long-term persistent outcomes.
Li T; Trinh T; Bosco A; Kiernan MC; Goldstein D; Park SB
Support Care Cancer; 2024 Apr; 32(5):278. PubMed ID: 38592525
[TBL] [Abstract][Full Text] [Related]
26. Vincristine-induced neuropathy as the initial presentation of charcot-marie-tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study.
Chauvenet AR; Shashi V; Selsky C; Morgan E; Kurtzberg J; Bell B;
J Pediatr Hematol Oncol; 2003 Apr; 25(4):316-20. PubMed ID: 12679647
[TBL] [Abstract][Full Text] [Related]
27. Severe Vincristine-induced Neuropathic Pain in a CYP3A5 Nonexpressor With Reduced CYP3A4/5 Activity: Case Study.
Bosilkovska M; Ing Lorenzini K; Uppugunduri CR; Desmeules J; Daali Y; Escher M
Clin Ther; 2016 Jan; 38(1):216-20. PubMed ID: 26565076
[TBL] [Abstract][Full Text] [Related]
28. Acute, long-term or non-vincristine-induced peripheral neuropathy among non-Hodgkin lymphoma survivors: Symptoms, daily activities, functional status, and quality of life.
Su YC; Lai YH; Hsieh ST; Teng CJ; Lee YH
Eur J Oncol Nurs; 2024 Apr; 69():102540. PubMed ID: 38461728
[TBL] [Abstract][Full Text] [Related]
29. Glutamine for the treatment of vincristine-induced neuropathy in children and adolescents with cancer.
Sands S; Ladas EJ; Kelly KM; Weiner M; Lin M; Ndao DH; Dave A; Vahdat LT; Bender JG
Support Care Cancer; 2017 Mar; 25(3):701-708. PubMed ID: 27830395
[TBL] [Abstract][Full Text] [Related]
30. Variants in vincristine pharmacodynamic genes involved in neurotoxicity at induction phase in the therapy of pediatric acute lymphoblastic leukemia.
Martin-Guerrero I; Gutierrez-Camino A; Echebarria-Barona A; Astigarraga I; Garcia de Andoin N; Navajas A; Garcia-Orad A
Pharmacogenomics J; 2019 Dec; 19(6):564-569. PubMed ID: 30723315
[TBL] [Abstract][Full Text] [Related]
31. A Metabolomics Approach for Early Prediction of Vincristine-Induced Peripheral Neuropathy.
Verma P; Devaraj J; Skiles JL; Sajdyk T; Ho RH; Hutchinson R; Wells E; Li L; Renbarger J; Cooper B; Ramkrishna D
Sci Rep; 2020 Jun; 10(1):9659. PubMed ID: 32541868
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of histone deacetylase 6 (HDAC6) protects against vincristine-induced peripheral neuropathies and inhibits tumor growth.
Van Helleputte L; Kater M; Cook DP; Eykens C; Rossaert E; Haeck W; Jaspers T; Geens N; Vanden Berghe P; Gysemans C; Mathieu C; Robberecht W; Van Damme P; Cavaletti G; Jarpe M; Van Den Bosch L
Neurobiol Dis; 2018 Mar; 111():59-69. PubMed ID: 29197621
[TBL] [Abstract][Full Text] [Related]
33. P-glycoprotein and Mrp1 collectively protect the bone marrow from vincristine-induced toxicity in vivo.
van Tellingen O; Buckle T; Jonker JW; van der Valk MA; Beijnen JH
Br J Cancer; 2003 Nov; 89(9):1776-82. PubMed ID: 14583783
[TBL] [Abstract][Full Text] [Related]
34. Antinociceptive effectiveness of Tithonia tubaeformis in a vincristine model of chemotherapy-induced painful neuropathy in mice.
Nawaz NUA; Saeed M; Rauf K; Usman M; Arif M; Ullah Z; Raziq N
Biomed Pharmacother; 2018 Jul; 103():1043-1051. PubMed ID: 29710662
[TBL] [Abstract][Full Text] [Related]
35. Vincristine neuropathy: neurophysiological and genetic studies in a case of Wilms tumor.
Schiavetti A; Frascarelli M; Uccini S; Novelli A
Pediatr Blood Cancer; 2004 Oct; 43(5):606-9. PubMed ID: 15382281
[TBL] [Abstract][Full Text] [Related]
36. Vincristine hyperalgesia in the rat: a model of painful vincristine neuropathy in humans.
Aley KO; Reichling DB; Levine JD
Neuroscience; 1996 Jul; 73(1):259-65. PubMed ID: 8783247
[TBL] [Abstract][Full Text] [Related]
37. Vincristine-induced neuropathy in childhood ALL (acute lymphoblastic leukemia) survivors: prevalence and electrophysiological characteristics.
Jain P; Gulati S; Seth R; Bakhshi S; Toteja GS; Pandey RM
J Child Neurol; 2014 Jul; 29(7):932-7. PubMed ID: 23781018
[TBL] [Abstract][Full Text] [Related]
38. Glutamate ameliorates experimental vincristine neuropathy.
Boyle FM; Wheeler HR; Shenfield GM
J Pharmacol Exp Ther; 1996 Oct; 279(1):410-5. PubMed ID: 8859020
[TBL] [Abstract][Full Text] [Related]
39. Vincristine-induced peripheral neurotoxicity: A prospective cohort.
Nama N; Barker MK; Kwan C; Sabarre C; Solimano V; Rankin A; Raabe J; Ross CJ; Carleton B; Zwicker JG; Rassekh SR
Pediatr Hematol Oncol; 2020 Feb; 37(1):15-28. PubMed ID: 31682156
[TBL] [Abstract][Full Text] [Related]
40. Evidence for direct axonal toxicity in vincristine neuropathy.
Silva A; Wang Q; Wang M; Ravula SK; Glass JD
J Peripher Nerv Syst; 2006 Sep; 11(3):211-6. PubMed ID: 16930282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
